12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Cosmos Holdings (NASDAQ:COSM) stock increased by 20.5% to $0.52 during Monday’s pre-market session. The company’s market cap…
CinCor Pharma Announces Topline Data For Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat On Uncontrolled Hypertension Did Not Meet Its Primary Endpoint
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP)
12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup
Expert Ratings for CinCor Pharma
Analysts have provided the following ratings for CinCor Pharma (NASDAQ:CINC) within the last quarter:
Goldman Sachs Initiates Coverage On CinCor Pharma with Buy Rating, Announces Price Target of $67
Goldman Sachs analyst Madhu Kumar initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Buy rating and announces Price Target of $67.
CinCor Pharma Announces Late-Breaking Presentation Of Phase 2 BrigHtn Data For Baxdrostat In Treatment-Resistant Hypertension At The Upcoming 2022 American Heart Association Scientific Sessions : November 7
WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with
Analyst Ratings for CinCor Pharma
Over the past 3 months, 5 analysts have published their opinion on CinCor Pharma (NASDAQ:CINC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Maintains Overweight on CinCor Pharma, Raises Price Target to $60
Morgan Stanley analyst Jeffrey Hung maintains CinCor Pharma (NASDAQ:CINC) with a Overweight and raises the price target from $45 to $60.
Piper Sandler Initiates Coverage On CinCor Pharma with Overweight Rating, Announces Price Target of $73
Piper Sandler analyst Yasmeen Rahimi initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Overweight rating and announces Price Target of $73.